Comparison of the hemodynamic stability of remimazolam versus dexmedetomidine during ultrasound-guided radiofrequency ablation of hepatic tumor under monitored anesthesia care
Not Applicable
- Conditions
- Neoplasms
- Registration Number
- KCT0007244
- Lead Sponsor
- Asan Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
Patients undergoing ultrasound-guided percutaneous liver radiofrequency ablation under monitored anesthesia care
Exclusion Criteria
1. Patients with a history of drug allergy to dexmedetomidine, benzodiazepine, or opioid analgesics
2. Patients with contraindications to dexmedetomidine, remimazolam, or remifentanil
3. Patients with body classification 3 or higher by the American Society of Anesthesiologists Physical Status
4. Patients with a body mass index of 35 or higher
5. Child-Pugh class C cirrhosis
6. Patients undergoing dialysis for end-stage renal disease
7. Patients scheduled for RFA under general anesthesia
8. Patients judged to be inappropriate by other researchers
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Composite incidence of bradycardia and hypotension
- Secondary Outcome Measures
Name Time Method total remifentanil dose ;awakening time;post-anesthesia care unit stay time